CoChat
Sign Up
Cited by 201

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial

Bruno, Savino, Maisonneuve, Patrick, Castellana, Paola, Rotmensz, Nicole, Rossi, Sonia, Maggioni, Marco, Persico, Marcello, Colombo, Alberto, Monasterolo, Franco, Casadei-Giunchi, Donata, Desiderio, Franco, Stroffolini, Tommaso, Sacchini, Virgilio, Decensi, Andrea, Veronesi, Umberto·2005·BMJ
DOI 10.1136/bmj.38391.663287.e0
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.38391.663287.e0

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Diabetes or obesity may increase the risk of liver injury induced by certain drugs such as tamoxifen and methotrexate.

    “Current evidence does not support the opinion that diabetes or obesity increase susceptibility to all-cause DILI [5], although they may increase the risk of liver injury induced by certain drugs such as tamoxifen and methotrexate [44,45].”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [44]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 23

  1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
  2. Pratt DS, Knox TA, Erban J. Tamoxifen induced steatohepatitis. Ann Intern Med 1995;123:236.
  3. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 1996;124:855-6.
  4. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999;353:36-7.
  5. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Preven- tion of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
  6. Veronesi U. Prevention of breast cancer with tamoxifen: the Italian study in hysterect- omized women. The Breast 1995;4:267-72.
  7. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-8.
  8. Brunt EM, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastro- enterol 1999;94:2467-74.
  9. Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 2001;54:945-51.
  10. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
  11. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Non-alcoholic fatty liver, steatohepatitis and metabolic syndrome. Hepatology 2003;37:917-23.
  12. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
  13. Lainè F, Bendavid G, Moirand R, Tessier S, Perrin N, Guillygomarc'h A, et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alco- hol consumption. Hepatology 2004;39:1639-46.
  14. Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. Am J Roentgenol 2003;180:129-34.
  15. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibro- sis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-42.
  16. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-7.
  17. Clark JM, Brancati FL, Diehl AM. Non-alcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
  18. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
  19. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1345-55.
  20. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Crucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
  21. Powell EE, Cooksley GE, Hanson R, Searle J, Halliday JW Powell LW. The natural his- tory of nonalcoholic steatohepatitis: a follow up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
  22. Adams LA, Keach J, Lindor KD, Angulo P. Time course of fibrosis progression in patients with non alcoholic fatty liver disease. Hepatology 2003;38:104.
  23. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Fre- quency of non-alcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-14. (Accepted 28 January 2005) doi 10.1136/bmj.38391.663287.E0 Liver Unit, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Corso di Porta Nuova 23, 20121 Milan, Italy · DOI

Cited by

Sorted by citations

Metadata

Authors
Bruno, S., Maisonneuve, P., Castellana, P., Rotmensz, N., Rossi, S., Maggioni, M., Persico, M., Colombo, A., Monasterolo, F., Casadei-Giunchi, D., Desiderio, F., Stroffolini, T., Sacchini, V., Decensi, A., & Veronesi, U.
Venue
BMJ
Publisher
BMJ
Published
2005-03-03
Volume
330
Issue
7497
Pages
932
ISSN
  • 0959-8138
  • 1468-5833
DOI
10.1136/bmj.38391.663287.e0
Cited by
201
References
1
Language
en
Licence
www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review